A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

Required: KRAS mutation

metastatic colorectal adenocarcinoma with kirsten rat sarcoma viral oncogene homolog (KRAS) mutations, detected by any Clinical Laboratory Improvement Amendments-certified method (tumor or ct-DNA)

Must have received: fluoropyrimidine (5-FU, capecitabine)

progression of disease on 5-FU or capecitabine

Must have received: platinum-based chemotherapy (oxaliplatin)

progression of disease on ... oxaliplatin

Must have received: topoisomerase inhibitor (irinotecan)

progression of disease on ... irinotecan

Must have received: anti-VEGF therapy (bevacizumab)

progression of disease on ... bevacizumab therapy or any other approved anti-VEGF therapy

Must have received: immunotherapy (anti-PD-L1, anti-CTLA4)

If participant has high levels of MicroSatellite Instability (MSI-H), they must have had recommended immunotherapy agent(s) i.e anti- programmed death ligand 1 (L)1 with or without anti-CTLA4 agents.

Cannot have received: (Lonsurf, regorafenib)

No prior Lonsurf or regorafenib treatment is allowed.

Cannot have received: MEK inhibitor

Must have not had any treatment with prior MEK (mitogen-activated protein kinase kinase) inhibitor

Cannot have received: anti-EGFR therapy

Must have not had any treatment with prior ... anti-EGFR (antineoplastic epidermal growth factor receptor)

Cannot have received: KRAS inhibitor

Must have not had any treatment with prior ... KRAS ... inhibitor therapy

Cannot have received: SOS1 inhibitor

Must have not had any treatment with prior ... SOS1 ( Son of sevenless 1) ... inhibitor therapy

Cannot have received: SHP2 inhibitor

Must have not had any treatment with prior ... SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase-2) inhibitor therapy

Cannot have received: cytotoxic chemotherapy

Exception: within 2 weeks prior to entering the study

Participants should not have had chemotherapy ... within 2 weeks prior to entering the study.

Cannot have received: radiation therapy

Exception: within 2 weeks prior to entering the study

Participants should not have had ... radiotherapy ... within 2 weeks prior to entering the study.

Cannot have received: surgery

Exception: major surgery within 2 weeks prior to entering the study

Participants should not have had ... major surgery within 2 weeks prior to entering the study.

Cannot have received: allogeneic stem cell transplant

No prior allogeneic stem cell or solid organ transplantation.

Cannot have received: solid organ transplant

No prior allogeneic stem cell or solid organ transplantation.